Central Nervous System Metastases in Breast Cancer
Gardado en:
| Publicado en: | Current Treatment Options in Oncology vol. 26, no. 1 (Jan 2025), p. 14 |
|---|---|
| Autor Principal: | |
| Outros autores: | , , |
| Publicado: |
Springer Nature B.V.
|
| Materias: | |
| Acceso en liña: | Citation/Abstract Full Text Full Text - PDF |
| Etiquetas: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3254822764 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1527-2729 | ||
| 022 | |a 1534-6277 | ||
| 024 | 7 | |a 10.1007/s11864-024-01286-1 |2 doi | |
| 035 | |a 3254822764 | ||
| 045 | 2 | |b d20250101 |b d20250131 | |
| 084 | |a 175828 |2 nlm | ||
| 100 | 1 | |a Grinda, Thomas |u Harvard Medical School, Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Department of Cancer Medicine, Gustave Roussy, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) | |
| 245 | 1 | |a Central Nervous System Metastases in Breast Cancer | |
| 260 | |b Springer Nature B.V. |c Jan 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Opinion StatementBreast cancer metastasizing to the central nervous system (CNS) encompasses two distinct entities: brain metastases involving the cerebral parenchyma and infiltration of the leptomeningeal space, i.e., leptomeningeal disease. CNS metastases affect 10–15% of patients with hormone receptor-positive-status and nearly one-half of those with HER2-positive and triple-negative breast cancer with distant metastatic disease. Significant clinical morbidity and heterogeneous penetration of the blood–brain barrier by systemic therapies contribute to the poor prognosis associated with brain metastases. Recent advances in radiotherapy, including stereotactic approaches and morbidity-reducing strategies such as the use of memantine and hippocampal avoidance in whole brain radiation, coupled with the development of more effective CNS-penetrant systemic therapies, including small molecules and antibody–drug conjugates, have significantly improved patient outcomes. Consequently, patients with breast cancer CNS metastases have improved survival compared to prior decades, and longitudinal care has become increasingly complex, necessitating a multidisciplinary approach to achieve optimal outcomes for patients. | |
| 651 | 4 | |a United States--US | |
| 653 | |a Medical diagnosis | ||
| 653 | |a Hippocampus | ||
| 653 | |a Memantine | ||
| 653 | |a Morbidity | ||
| 653 | |a Medical prognosis | ||
| 653 | |a Metastasis | ||
| 653 | |a Radiosurgery | ||
| 653 | |a Blood-brain barrier | ||
| 653 | |a Epidemiology | ||
| 653 | |a Parenchyma | ||
| 653 | |a Effectiveness | ||
| 653 | |a Radiation therapy | ||
| 653 | |a Breast cancer | ||
| 653 | |a Nervous system | ||
| 653 | |a Central nervous system | ||
| 653 | |a Metastases | ||
| 653 | |a Meninges | ||
| 653 | |a ErbB-2 protein | ||
| 700 | 1 | |a Aizer, Ayal A. |u Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Department of Radiation Oncology, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294) | |
| 700 | 1 | |a Lin, Nancy U. |u Harvard Medical School, Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) | |
| 700 | 1 | |a Sammons, Sarah L. |u Harvard Medical School, Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) | |
| 773 | 0 | |t Current Treatment Options in Oncology |g vol. 26, no. 1 (Jan 2025), p. 14 | |
| 786 | 0 | |d ProQuest |t Consumer Health Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3254822764/abstract/embedded/J7RWLIQ9I3C9JK51?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3254822764/fulltext/embedded/J7RWLIQ9I3C9JK51?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3254822764/fulltextPDF/embedded/J7RWLIQ9I3C9JK51?source=fedsrch |